N-(3-(3-(4-(1-Aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenethyl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amide

ID: ALA5220162

Chembl Id: CHEMBL5220162

PubChem CID: 139483041

Max Phase: Preclinical

Molecular Formula: C53H58N10O9

Molecular Weight: 979.11

Associated Items:

Names and Identifiers

Canonical SMILES:  Nc1ncccc1-c1nc2ccc(-c3cccc(CCNC(=O)CCOCCOCCOCCOCCNc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)c3)nc2n1-c1ccc(C2(N)CCC2)cc1

Standard InChI:  InChI=1S/C53H58N10O9/c54-47-39(8-3-22-58-47)48-60-42-15-14-40(59-49(42)62(48)37-12-10-36(11-13-37)53(55)20-4-21-53)35-6-1-5-34(33-35)18-23-57-44(64)19-25-69-27-29-71-31-32-72-30-28-70-26-24-56-41-9-2-7-38-46(41)52(68)63(51(38)67)43-16-17-45(65)61-50(43)66/h1-3,5-15,22,33,43,56H,4,16-21,23-32,55H2,(H2,54,58)(H,57,64)(H,61,65,66)

Standard InChI Key:  NKDSSNPBDZZURJ-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5220162

    ---

Associated Targets(Human)

AKT1 Tchem CRBN/AKT1 (26 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 979.11Molecular Weight (Monoisotopic): 978.4388AlogP: 4.70#Rotatable Bonds: 24
Polar Surface Area: 257.24Molecular Species: BASEHBA: 16HBD: 5
#RO5 Violations: 2HBA (Lipinski): 19HBD (Lipinski): 7#RO5 Violations (Lipinski): 3
CX Acidic pKa: 11.59CX Basic pKa: 9.65CX LogP: 3.86CX LogD: 1.78
Aromatic Rings: 6Heavy Atoms: 72QED Weighted: 0.04Np Likeness Score: -0.73

References

1. Yu X, Xu J, Cahuzac KM, Xie L, Shen Y, Chen X, Liu J, Parsons RE, Jin J..  (2022)  Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.,  65  (20.0): [PMID:36197750] [10.1021/acs.jmedchem.2c01454]

Source